Equities analysts predict that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will announce earnings per share (EPS) of $1.31 for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Lexicon Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $1.12 and the highest estimate coming in at $1.49. Lexicon Pharmaceuticals reported earnings per share of ($0.26) in the same quarter last year, which would indicate a positive year over year growth rate of 603.8%. The business is expected to report its next earnings report on Thursday, November 7th.
According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of ($0.17) per share for the current year, with EPS estimates ranging from ($1.89) to $0.73. For the next fiscal year, analysts anticipate that the company will report earnings of ($1.73) per share, with EPS estimates ranging from ($2.15) to ($1.49). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.13). The company had revenue of $9.68 million for the quarter, compared to analysts’ expectations of $28.52 million. Lexicon Pharmaceuticals’s revenue was down 29.9% compared to the same quarter last year. During the same period last year, the business posted ($0.33) EPS.
In other news, Director Christopher J. Sobecki purchased 25,000 shares of Lexicon Pharmaceuticals stock in a transaction dated Monday, September 16th. The stock was acquired at an average cost of $2.55 per share, for a total transaction of $63,750.00. Following the acquisition, the director now directly owns 112,493 shares in the company, valued at $286,857.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Lonnel Coats purchased 50,000 shares of Lexicon Pharmaceuticals stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average price of $3.13 per share, with a total value of $156,500.00. Following the completion of the acquisition, the chief executive officer now owns 127,639 shares in the company, valued at $399,510.07. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 289,749 shares of company stock worth $618,230. 6.40% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of LXRX. First Manhattan Co. increased its position in Lexicon Pharmaceuticals by 7.3% in the 2nd quarter. First Manhattan Co. now owns 2,949,979 shares of the biopharmaceutical company’s stock worth $18,555,000 after buying an additional 201,393 shares during the period. Voloridge Investment Management LLC bought a new stake in shares of Lexicon Pharmaceuticals during the second quarter valued at approximately $105,000. Pictet Asset Management Ltd. grew its position in Lexicon Pharmaceuticals by 13.4% in the second quarter. Pictet Asset Management Ltd. now owns 665,776 shares of the biopharmaceutical company’s stock valued at $4,188,000 after acquiring an additional 78,926 shares during the period. Price T Rowe Associates Inc. MD grew its position in Lexicon Pharmaceuticals by 77.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 61,642 shares of the biopharmaceutical company’s stock valued at $388,000 after acquiring an additional 26,900 shares during the period. Finally, Morgan Stanley grew its position in Lexicon Pharmaceuticals by 158.0% in the second quarter. Morgan Stanley now owns 195,307 shares of the biopharmaceutical company’s stock valued at $1,229,000 after acquiring an additional 119,611 shares during the period. Hedge funds and other institutional investors own 98.87% of the company’s stock.
LXRX traded down $0.16 during trading on Thursday, hitting $3.20. The stock had a trading volume of 1,353,803 shares, compared to its average volume of 3,491,887. Lexicon Pharmaceuticals has a twelve month low of $1.13 and a twelve month high of $11.51. The firm has a market capitalization of $378.33 million, a P/E ratio of -2.81 and a beta of 0.75. The company’s 50-day moving average price is $1.76 and its 200 day moving average price is $4.86.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Recommended Story: Moving Average Convergence Divergence (MACD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.